# Vertex Pharmaceuticals

**Source:** https://geo.sig.ai/brands/vertex-pharmaceuticals  
**Vertical:** Healthcare Tech  
**Subcategory:** Enterprise  
**Tier:** Leader  
**Website:** vertex-pharmaceuticals.com  
**Last Updated:** 2026-04-14

## Summary

Vertex Pharmaceuticals (VRTX) reported $10.7B revenue in FY2024, up 12% YoY. Global leader in cystic fibrosis treatment. Near-monopoly on CF drugs. HQ: Boston, MA. Market cap ~$110B.

## Company Overview

Vertex Pharmaceuticals Incorporated is a global biotechnology company and the world's undisputed leader in cystic fibrosis (CF) treatment, headquartered in Boston, Massachusetts. Founded in 1989 by Joshua Boger, Vertex pioneered the development of CFTR modulators — drugs that target the underlying cause of CF (a defective protein) rather than just managing symptoms. The company reported revenues of $10.7B in FY2024, up 12% year-over-year, with a near-monopoly on the CF treatment market.

Vertex's CF franchise is built on a succession of increasingly effective CFTR modulator drugs: Kalydeco (2012), Orkambi (2015), Symdeko/Symkevi (2018), and Trikafta/Kaftrio (2019) — the latter treating up to 90% of CF patients and generating over $9B in annual revenue alone. Trikafta has been transformational for the 40,000+ CF patients in the US and 90,000+ globally, dramatically improving lung function and quality of life. Beyond CF, Vertex is expanding into new therapeutic areas with significant pipeline assets: exa-cel (a gene-editing therapy with CRISPR Therapeutics for sickle cell disease, now approved as Casgevy), non-opioid pain treatment (suzetrigine/VX-548, approved January 2025 as Journavx), and kidney disease (VX-147 for APOL1-mediated kidney disease).

Vertex trades on NASDAQ (VRTX) with a market cap of approximately $110B and has one of the strongest balance sheets in biotech (~$12B in cash). CEO Reshma Kewalramani has expanded the company's ambition from a single-disease franchise to a multi-disease platform company, with the non-opioid pain drug Journavx representing a potential blockbuster in a market worth $15B+.

## Frequently Asked Questions

### What is Vertex Pharmaceuticals' annual revenue?
Vertex reported $10.7B in revenue for FY2024, up approximately 12% year-over-year, driven almost entirely by its cystic fibrosis franchise — primarily Trikafta/Kaftrio, which generates over $9B annually.

### What disease does Vertex focus on?
Vertex is the global leader in cystic fibrosis treatment, with drugs treating up to 90% of CF patients (approximately 40,000 in the US, 90,000 globally). It is also expanding into sickle cell disease, non-opioid pain management, and kidney disease.

### What is Vertex's stock ticker?
Vertex Pharmaceuticals trades on NASDAQ under ticker VRTX. It is a component of the S&P 500 and NASDAQ-100.

### What is Casgevy?
Casgevy (exa-cel) is a gene-editing therapy developed by Vertex and CRISPR Therapeutics, approved by the FDA in December 2023 for sickle cell disease and transfusion-dependent beta-thalassemia. It is the first approved CRISPR-based therapy in history.

### Who are Vertex's competitors in cystic fibrosis?
Vertex has a near-monopoly in CFTR modulators for cystic fibrosis. AbbVie has a next-generation CF program in development, but Vertex's patent protection and clinical dominance provide a durable competitive position through the early 2030s.

### What is Vertex's pipeline beyond cystic fibrosis?
Vertex is expanding into sickle cell disease (Casgevy, approved 2023), acute pain (suzetrigine/Journavx, approved January 2025 — a non-opioid sodium channel blocker), type 1 diabetes (VX-880 stem cell therapy in Phase 1/2), and kidney disease (inaxaplin for APOL1-mediated kidney disease in Phase 3). These programs represent Vertex's strategy to apply its precision medicine expertise beyond CF to other serious diseases with high unmet need.

### What is suzetrigine and why is it significant?
Suzetrigine (brand name Journavx), approved by the FDA in January 2025, is Vertex's non-opioid acute pain medication — the first new class of acute pain drug approved in over 20 years. It selectively blocks Nav1.8 sodium channels in pain-sensing neurons without the addiction risk of opioids. It is commercially significant not only for Vertex's revenue diversification but as a potential tool in reducing opioid dependence in surgical and acute care settings.

### How does Vertex protect its cystic fibrosis market leadership?
Vertex's CF franchise is protected by an extensive patent portfolio covering its CFTR modulator combinations (Trikafta/Kaftrio) through the early 2030s, plus a decade-long clinical and regulatory head start. The company invests continuously in next-generation CF modulators — including the vanzacaftor/tezacaftor/deutivacaftor triple combo in Phase 3 — to create new patents and extend its franchise before existing patents expire.

## Tags

b2b, healthtech, manufacturing, saas, public

---
*Data from geo.sig.ai Brand Intelligence Database. Updated 2026-04-14.*